Hengrui Medicine’s Cancer Drug Passes Clinical Stage
This article was originally published in PharmAsia News
Executive Summary
Jiangsu Hengrui Medicine Co. Ltd. has obtained approval for its clinical trial results for targeting anti-tumor drug irinotecan Hydrochloride Liposome Injection by HPLC, which will belong to the Camptosar (irinotecan) drug series once launched.